obesity

The collaboration leverages JW Pharmaceutical’s established research and development capabilities to accelerate the drug’s entry into South Korea’s growing metabolic disease sector.

Foundayo (orforglipron) is the first once-daily oral GLP-1 approved for weight management with no restrictions on food, water, or timing.

When combined with a reduced-calorie diet and regular physical activity, Foundayo helps patients shed excess weight and maintain their progress.

The drug works as a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, requiring no food or water restrictions before taking it.

A central focus of the partnership is equipping family physicians and other healthcare professionals to better identify and support individuals at risk.

Awiqli® changes that by offering a single weekly dose, giving patients greater flexibility to fit treatment into their individual lifestyles and preferences.

Wegovy HD became the fourth drug to receive FDA approval through the Commissioner’s National Priority Voucher pilot programme.

The companies are competing for a share of India’s Semaglutide market, which analysts estimate will reach USD1 billion over the next two years.

Pfizer secured marketing rights to the GLP-1 compound ecnoglutide through a partnership with Hangzhou-based Sciwind Biosciences announced last month.